Cytogenix (fka CYGX)

[LongJohnSilver]

NEWS NEWS NEWS....

News for 'CYGX' - (CytoGenix and Eurogentec Align on synDNA(TM)
Development)

HOUSTON, May 10, 2007 (BUSINESS WIRE) -- CytoGenix, Inc. (OTCBB:CYGX)
announcedtodaythat it has executed a Letter of Intent regarding synDNA(TM) development
with Eurogentec S.A.The Companies have identified an area of mutual interest regarding
developmentofsynDNA(TM) and will collaborate to optimize manufacturing and to implement
purification and quality control parameters. A successful collaboration
willfacilitatesubmission of European Union (EU) regulatory filings with products
containing synDNA(TM).Malcolm Skolnick, CytoGenix President/CEO, stated, "Eurogentec is an
excellentprocessdevelopment partner for synDNA(TM). The collaboration will allow us to
accelerate the entry of synDNA(TM) as a drug substance for clients within
theEU.Eurogentec brings a wealth of process development and EU regulatory filing
experience to the collaboration."Dr. Phillippe Cronet, Director of Eurogentec's Biologics Business Unit,
commented, "CytoGenix synDNA(TM) has the potential to make a significant
impactasa source of drug substance for a wide array of DNA-based medicine. We are
looking forward to establishing a collaborative relationship with
CytoGenix."CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops
andmarketsinnovative products and services based on its proprietary synDNATM
production and ssDNA expression technology. The company has developed abreakthroughsynthetic process for large-scale production of high purity DNA
that can be made faster and cleaner than production using traditionalfermentationmethods and has developed a novel expression vector that enables
production of ssDNA sequences inside the cell. CytoGenix currently holds
11grantedpatents and about 36 international or US pending patent applications
claiming methods and materials in connection with these platform
technologies.Regarding Eurogentec

Eurogentec was founded in 1985 as a spin-off of the University of Liege(Belgium).Its mission is to design and deliver reliable and innovative services
and products for the Life-Science community. As a leading supplier for
genomicandproteomic research, Eurogentec is able to offer its customers integrated
solutions, whether they use DNA, antibodies, peptides or proteins as
researchtools.Eurogentec also offers research and development services for the
biopharmaceutical industry.During the past years, Eurogentec has developed a broad platform of
enablingtechnologies.The activities are organised around 2 business units.

The Tools for Genomics and Proteomics department offers oligonucleotidesynthesiswith a large range of modifications, oligonucleotides for In Vitro
Diagnostic (IVD), Real-Time PCR products, DNA MicroArray services and a
widerangeof kits and consumables. It also gathers know-how in the design of
peptides, either for antibody production or bioactive peptide purposes.
Antibodyproductionin a wide range of animal models as well as Peptide-, Antibody- and
ProteinArrays are also amongst its expertise.Eurogentec's Biologics unit is a full-service Contract Manufacturing
Organisation (CMO) delivering research, development and production
services forcGMPclinical batch manufacturing.

The EGT Group currently employs around 300 people, including around 30
PhDs. In2001,Eurogentec has been awarded "Belgium's entrepreneur of the Year." In 2002,
Eurogentec received the Walloon Region award for exports in Europe.SAFE HARBOR: Except for statements of historical fact, the statements in
thispressrelease are forward-looking. Such statements are subject to a number of
risks and uncertainties that could cause actual results to differ
materiallyfromthe statements made. These factors include, but are not limited to,
generaleconomicconditions, risks associated with the acceptance of new products,
competition, and other factors more fully detailed in the company's
filings withtheSecurities and Exchange Commission. Additional information about CytoGenix
and its technology can be found on the website at www.cytogenix.com.SOURCE: CytoGenix, Inc.

CONTACT: CytoGenix, Inc., HoustonCEOMalcolm Skolnick,
713-789-0070http://www.cytogenix.com/orEurogentec S.A.CEOJean-Pierre
Delwart, + 32 4 372 74 [e-mail]
BiologicsPhilippe Cronet, + 32 4 372 74
[e-mail] ManagerIsabelle Body, + 32 4 372
74 [e-mail]: + 32 4 372 75
[e-mail] Business Wire 2007